Provided by Tiger Trade Technology Pte. Ltd.

CRISPR Therapeutics AG

49.07
+0.33000.68%
Volume:509.28K
Turnover:24.61M
Market Cap:4.68B
PE:-8.79
High:49.07
Open:48.31
Low:47.38
Close:48.74
52wk High:78.48
52wk Low:30.04
Shares:95.30M
Float Shares:90.53M
Volume Ratio:0.79
T/O Rate:0.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.5830
EPS(LYR):-4.3416
ROE:-25.33%
ROA:-13.28%
PB:2.44
PE(LYR):-11.30

Loading ...

IBM, P&G, GameStop, Crispr, AGNC: Insider Moves Exposed

TIPRANKS
·
Jan 31

Cathie Wood’s ARK Investment buys 127K shares of Crispr Therapeutics today

TIPRANKS
·
Jan 30

Assessing CRISPR Therapeutics (CRSP) Valuation After Recent Share Price Movements

Simply Wall St.
·
Jan 29

Top Executive Makes Bold Move With Fresh Crispr Therapeutics AG Stock Buy

TIPRANKS
·
Jan 28

CRISPR Therapeutics AG CFO Prasad Raju Reports Disposal of Common Shares

Reuters
·
Jan 27

CRISPR Therapeutics CEO Samarth Kulkarni Reports Disposal of Common Shares

Reuters
·
Jan 23

BofA Securities Adjusts Price Target on CRISPR Therapeutics AG to $89 From $90, Maintains Buy Rating

MT Newswires Live
·
Jan 22

Is It Time To Reassess CRISPR Therapeutics (CRSP) After Recent Gene Editing Progress?

Simply Wall St.
·
Jan 18

Not Just for Medical Inquiries: AI Healthcare Is Becoming the Next Golden Track

TradingKey
·
Jan 16

CRISPR Therapeutics Advances CTX310 and CTX320 Gene Editing Drugs in New Clinical Trials

Reuters
·
Jan 12

CRISPR Therapeutics AG Outlines 2026 Strategy with CASGEVY® Expansion, Advancement of Cardiovascular and Autoimmune Programs, siRNA Pipeline Growth, and Initiation of New Clinical Trials

Reuters
·
Jan 12

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

GlobeNewswire
·
Jan 12

CRISPR Therapeutics Ag : Bernstein Raises Target Price to $50 From $43

THOMSON REUTERS
·
Jan 12

BofA Adjusts Price Target on CRISPR Therapeutics to $90 From $93, Maintains Buy Rating

MT Newswires Live
·
Jan 06

Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks

Benzinga_recent_news
·
Jan 01

CRISPR Therapeutics CFO Prasad Raju Reports Sale of Common Shares

Reuters
·
Dec 24, 2025

CRISPR Therapeutics Launches Phase 1 Basket Trial of Zugo-cel in Autoimmune Hematologic Diseases

Reuters
·
Dec 22, 2025

How Investors May Respond To CRISPR Therapeutics (CRSP) Earnings Amid Slow Casgevy Uptake Concerns

Simply Wall St.
·
Dec 20, 2025

Why Intellia Therapeutics (NTLA) Is Up 6.9% After Disclosing Serious Liver Safety Events In Lead CRISPR Trials

Simply Wall St.
·
Dec 08, 2025

Why CRISPR Therapeutics (CRSP) Is Up 6.1% After Positive CTX310 Trial and Earnings Beat

Simply Wall St.
·
Nov 29, 2025